Acetyl Gastric Inhibitory Peptide (human) (TFA) (Synonyms: Human N-acetyl GIP TFA) |
| Catalog No.GC68604 |
Acetyl Gastric Inhibitory Peptide (human) (TFA)는 합성된, 화학적으로 변형된 인간 위장억제 펩타이드이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 299898-52-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Acetyl Gastric Inhibitory Peptide (human) (TFA)는 합성된, 화학적으로 변형된 인간 위장억제 펩타이드이다. Acetyl Gastric Inhibitory Peptide (human) (TFA)는 포도당에 따라 인슐린 분비를 효과적으로 자극하는 생리적인 인크레틴 호르몬이다. Acetyl Gastric Inhibitory Peptide (human) (TFA)는 대사성 질환 연구와 당뇨병 약물 개발에 일반적으로 사용된다[3-4].
성채 수컷 위스타 쥐에서 Acetyl Gastric Inhibitory Peptide (human) (TFA) (25nM/kg; ip; 단일 주사)는 혈장 포도당 농도를 유의하게 감소시킨다[5].
References:
[1]. Flatt PR, O'harte FP, Utech Ltd. Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function. United States patent application US 11/991,638. 2009 Nov 19.
[2]. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 2009 Sep; 52: 1724-1731.
[3]. Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020 Mar; 125: 170202.
[4]. O'Harte F, Gault V, Parker J, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep; 45: 1281-1291.
[5]. Cassidy RS, Irwin N, Flatt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Biological chemistry. 2008 Feb; 389(2): 189-193.
| 동물 실험 [1]: | |
동물 모형 | 성채 수컷 위스타 쥐 |
제조 방법 | 복강 주사로 생리 식염수(0.9%, w/v, NaCl)나 포도당[체중당 18 mmol/kg]을 단독으로 투여하거나 천연 위장억제 펩타이드(GIP), GLP-1, Acetyl Gastric Inhibitory Peptide (human) (TFA), GIP(Lys37)PAL, N-AcGIP(Lys37)PAL, (Pro3)GIP 또는 (Pro3)GIP와 GIP(모두 25nM/kg b.w.)를 함께 투여한 후 혈장 포도당과 혈청 글루카곤 반응을 평가하였습니다. |
제형 | 25nM/kg; ip; 단일 주사 |
응용 분야 | Acetyl Gastric Inhibitory Peptide (human) (TFA)는 혈장 포도당 농도를 현저하게 감소시킵니다. |
References: | |
| Cas No. | 299898-52-5 | SDF | |
| Synonyms | Human N-acetyl GIP TFA | ||
| Formula | C228H340N60O67S.C2HF3O2 | M.Wt | 5139.62 |
| Solubility | H2O : 50 mg/mL (9.73 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 194.6 μL | 972.8 μL | 1.9457 mL |
| 5 mM | 38.9 μL | 194.6 μL | 389.1 μL |
| 10 mM | 19.5 μL | 97.3 μL | 194.6 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *